A
Alfred O. Mueck
Researcher at University of Tübingen
Publications - 271
Citations - 5011
Alfred O. Mueck is an academic researcher from University of Tübingen. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 37, co-authored 231 publications receiving 4364 citations. Previous affiliations of Alfred O. Mueck include Capital Medical University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Hormonal contraception and risk of cancer
David Cibula,Anne Gompel,Alfred O. Mueck,C. La Vecchia,Philip C Hannaford,Sven O. Skouby,Michal Zikan,Ladislav Dušek +7 more
TL;DR: Oral contraceptives have been found to have a significant protective effect on the risk of ovarian cancer, and the protection increases with duration of use (relative risk decreased by 20% for each 5 years of use) as mentioned in this paper.
Journal ArticleDOI
Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
TL;DR: Once-daily oral ospemifene 60 mg was effective for the treatment of VVA in postmenopausal women with vaginal dryness in a 12 week, multicentre, randomised, double-blind, parallel-group phase III study of women with VVA.
Journal ArticleDOI
Statins can inhibit proliferation of human breast cancer cells in vitro.
TL;DR: Data suggest that statins may have clinical significance in the primary prevention of human breast cancer beyond their cholesterol-lowering effect, however, clinical proof must be awaited before drawing any further conclusions.
Journal ArticleDOI
Smoking, estradiol metabolism and hormone replacement therapy.
Alfred O. Mueck,Harald Seeger +1 more
TL;DR: It has been proven that, depending on the type, duration and intensity of nicotine consumption, smoking can reduce or completely cancel the efficacy of orally administered estrogens, and women who continue to smoke despite all warnings should therefore only be treated via the transdermal route.
Journal ArticleDOI
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
Panagiotis Anagnostis,Stavroula A Paschou,Gesthimani Mintziori,Iuliana Ceausu,Herman Depypere,Irene Lambrinoudaki,Alfred O. Mueck,Faustino R. Pérez-López,Margaret Rees,Levent M. Senturk,Tommaso Simoncini,John C. Stevenson,Petra Stute,Florence Tremollieres,Dimitrios G. Goulis +14 more
TL;DR: No robust recommendations can be made for ibandronate and denosumab, despite the proven efficacy in the reduction of vertebral and non-vertebral fractures, because of the limited evidence.